- Home
- DMAC vs IDE Comparison
DMAC vs IDE Comparison
Compare DMAC & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- IDE
- Stock Information
- Founded
- DMAC 2000
- IDE 2010
- Country
- DMAC United States
- IDE United States
- Employees
- DMAC N/A
- IDE N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- IDE Finance/Investors Services
- Sector
- DMAC Health Care
- IDE Finance
- Exchange
- DMAC Nasdaq
- IDE Nasdaq
- Market Cap
- DMAC 190.2M
- IDE 165.7M
- IPO Year
- DMAC N/A
- IDE N/A
- Fundamental
- Price
- DMAC $4.36
- IDE $11.06
- Analyst Decision
- DMAC Strong Buy
- IDE
- Analyst Count
- DMAC 2
- IDE 0
- Target Price
- DMAC $7.00
- IDE N/A
- AVG Volume (30 Days)
- DMAC 67.1K
- IDE 33.5K
- Earning Date
- DMAC 11-11-2024
- IDE 01-01-0001
- Dividend Yield
- DMAC N/A
- IDE 8.83%
- EPS Growth
- DMAC N/A
- IDE N/A
- EPS
- DMAC N/A
- IDE N/A
- Revenue
- DMAC N/A
- IDE N/A
- Revenue This Year
- DMAC N/A
- IDE N/A
- Revenue Next Year
- DMAC N/A
- IDE N/A
- P/E Ratio
- DMAC N/A
- IDE N/A
- Revenue Growth
- DMAC N/A
- IDE N/A
- 52 Week Low
- DMAC $1.94
- IDE $8.61
- 52 Week High
- DMAC $4.95
- IDE $10.46
- Technical
- Relative Strength Index (RSI)
- DMAC 58.96
- IDE 55.63
- Support Level
- DMAC $4.11
- IDE $11.00
- Resistance Level
- DMAC $4.48
- IDE $11.38
- Average True Range (ATR)
- DMAC 0.20
- IDE 0.13
- MACD
- DMAC -0.00
- IDE -0.01
- Stochastic Oscillator
- DMAC 74.63
- IDE 48.39
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.